Bessemer Group Inc. Decreases Stake in Merck & Co., Inc. $MRK

Bessemer Group Inc. lowered its stake in shares of Merck & Co., Inc. (NYSE:MRK) by 47.3% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,081,897 shares of the company’s stock after selling 972,240 shares during the period. Bessemer Group Inc.’s holdings in Merck & Co., Inc. were worth $130,142,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Kingdom Financial Group LLC. acquired a new position in Merck & Co., Inc. during the fourth quarter worth $25,000. Prosperity Bancshares Inc acquired a new stake in Merck & Co., Inc. in the fourth quarter valued at $26,000. Abound Financial LLC purchased a new position in shares of Merck & Co., Inc. in the fourth quarter valued at $26,000. IFC & Insurance Marketing Inc. purchased a new position in shares of Merck & Co., Inc. in the fourth quarter valued at $31,000. Finally, High Note Wealth LLC raised its stake in shares of Merck & Co., Inc. by 58.9% during the 4th quarter. High Note Wealth LLC now owns 294 shares of the company’s stock worth $31,000 after buying an additional 109 shares during the last quarter. 76.07% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: The FDA approval of LIPFENDRA gives Merck its first oral PCSK9 inhibitor, opening a new revenue stream in cardiovascular care and strengthening its non-oncology portfolio. Reuters article on FDA approval
• Positive Sentiment: Analysts highlighted continued oncology pipeline progress, including FDA acceptance of multiple regulatory filings and Merck’s broader effort to offset the eventual 2028 Keytruda patent cliff. Seeking Alpha article on pipeline expansion
• Neutral Sentiment: Coverage also noted that Lipfendra’s launch is expected soon and that the drug could become a major product over time, though sales will depend on uptake, pricing, and competition from existing cholesterol therapies. Zacks article on Lipfendra launch
• Neutral Sentiment: There was also a rumor that Merck may be in a takeover battle for genomics company Personalis, but this appears speculative and is not confirmed. Yahoo Finance article on Personalis rumor

Analysts Set New Price Targets

Several analysts have issued reports on the stock. Morgan Stanley upped their price target on shares of Merck & Co., Inc. from $112.00 to $113.00 and gave the company an “equal weight” rating in a report on Thursday, July 9th. BMO Capital Markets lifted their price objective on Merck & Co., Inc. from $135.00 to $142.00 and gave the stock an “outperform” rating in a research report on Monday, July 13th. Wells Fargo & Company upped their target price on Merck & Co., Inc. from $145.00 to $150.00 and gave the company an “overweight” rating in a research note on Wednesday, July 8th. Citigroup began coverage on Merck & Co., Inc. in a report on Wednesday, May 6th. They set a “neutral” rating and a $125.00 target price on the stock. Finally, Royal Bank Of Canada reissued an “outperform” rating and set a $142.00 price target on shares of Merck & Co., Inc. in a research report on Wednesday, July 8th. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and seven have assigned a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $133.94.

Merck & Co., Inc. Stock Performance

NYSE:MRK opened at $127.47 on Friday. The firm’s fifty day simple moving average is $120.11 and its 200 day simple moving average is $116.94. The company has a current ratio of 1.30, a quick ratio of 1.06 and a debt-to-equity ratio of 1.02. Merck & Co., Inc. has a twelve month low of $76.66 and a twelve month high of $131.74. The firm has a market capitalization of $314.83 billion, a price-to-earnings ratio of 35.91, a PEG ratio of 4.40 and a beta of 0.19.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings results on Thursday, April 30th. The company reported ($1.28) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.47) by $0.19. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.The firm had revenue of $16.29 billion during the quarter, compared to analysts’ expectations of $15.85 billion. During the same quarter in the prior year, the business earned $2.22 EPS. Merck & Co., Inc.’s quarterly revenue was up 4.9% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. As a group, equities research analysts expect that Merck & Co., Inc. will post 3.17 earnings per share for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, July 8th. Investors of record on Monday, June 15th were given a dividend of $0.85 per share. The ex-dividend date was Monday, June 15th. This represents a $3.40 dividend on an annualized basis and a yield of 2.7%. Merck & Co., Inc.’s payout ratio is currently 95.77%.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.